Follow The Filings

BLTE Belite Bio

Belite Bio earnings company data as of 7:04 PM ET 11/19

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS -0.77 GAAP -0.65 —
Rev — — —

Insider trades

Open-market buys and sales by BLTE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BLTE insider trades
  • None no insider bought on the open market
  • $2.9M sold by 1 insider outside a trading plan
  • $38.1M sold by 5 insiders under 10b5-1 plans
  1. Hendrik Peter Scholl Chief Medical Officer
    Planned sale
    $332K 2,000 shares at $165.99 14% of stake
    Traded Nov 12 Filed Nov 16
  2. Hendrik Peter Scholl Chief Medical Officer
    Planned sale
    $83K 500 shares at $165.32 3.3% of stake
    Traded Oct 1 Filed Oct 5
  3. Yu-Hsin Lin CEO
    Planned sale
    $19.1M 100,435 shares at $190.00 59% of stake
    Traded Sep 4–8 Filed Sep 9
  4. Hao-Yuan Chuang CFO
    Planned sale
    $12.8M 67,395 shares at $189.98 72% of stake
    Traded Sep 4–8 Filed Sep 9
  5. Hao-Yuan Chuang CFO
    Planned sale
    $66K 367 shares at $180.35 0.4% of stake
    Traded Aug 12 Filed Aug 14
  6. Yu-Hsin Lin CEO
    Planned sale
    $66K 365 shares at $180.35 0.2% of stake
    Traded Aug 12 Filed Aug 14
  7. Hendrik Peter Scholl Chief Medical Officer
    Sale
    $1.5M 10,000 shares at $145.24 40% of stake
    Traded Jun 18 Filed Jun 22
  8. Hendrik Peter Scholl Chief Medical Officer
    Sale
    $1.4M 10,000 shares at $140.57 29% of stake
    Traded Jun 16 Filed Jun 17
  9. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $102K 666 shares at $153.21 100% of stake
    Traded May 7 Filed May 8
  10. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $154K 1,000 shares at $153.84 60% of stake
    Traded May 6 Filed May 7
  11. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.50 38% of stake
    Traded May 5 Filed May 6
  12. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.64 27% of stake
    Traded May 4 Filed May 5
  13. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.78 21% of stake
    Traded May 1 Filed May 4
  14. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $157K 1,000 shares at $156.97 18% of stake
    Traded Apr 30 Filed May 1
  15. Nathan L. Mata Chief Scientific Officer
    Planned sale
    $156K 1,000 shares at $155.82 15% of stake
    Traded Apr 29 Filed Apr 30

Also filed in the last 12 months, not counted as buying or selling: 4 other transactions and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
6-K FORM 6-K
424B5
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
6-K FORM 6-K
SCHEDULE 13G/A —
6-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf